Cytotoxic Potential Despite Impaired Activation Pathways in T Lymphocytes Infiltrating Nasopharyngeal Carcinoma
Overview
Authors
Affiliations
Nasopharyngeal carcinoma (NPC) is an epithelial tumor consistently associated with EBV. The histological picture is characterized by a strikingly abundant lymphocytic infiltrate. Furthermore, the epithelial tumor cells present several immunological characteristics which suggest an important role for tumor-infiltrating lymphocytes (TIL) in the biology of this tumor. The present study reports the phenotypic and functional characterization of TIL from NPC obtained after enzymatic digestion of 15 NPC biopsies. Flow cytometric analysis of TIL suspensions indicated that most TIL were mature CD3+ T lymphocytes (mean = 60%) with a variable CD4/CD8 ratio. Most TIL were TCR alpha/beta-positive (mean = 55%) and only a few TCR gamma-delta-positive cells could be identified. A small percentage (mean = 9%) displayed an activated phenotype (CD25+, HLA class II+). Using limiting dilution analysis, we found that the average frequency of proliferative T-lymphocyte precursors (PTL-P) is lower among TIL (1/40) than in autologous (1/7) or normal PBL (1/1.4). Moreover, sorting experiments have shown that this defect is significantly more pronounced in the CD8+ than in the CD4+ TIL subset. Accordingly, the TCR and the CD2-mediated antigen-independent pathways of activation were impaired. Different types of cytotoxic precursor could be detected. These included lectin-dependent cell cytotoxicity (LDCC) and NK-like or lymphokine-activated killer (LAK) activity. Interestingly, some TIL from NPC were able to lyse an NPC tumor (C15) maintained in nude mice. Thus, despite impaired activation pathways, the cytolytic potential of proliferating TIL in NPC is preserved.
Chak P, Kam N, Choi T, Dai W, Kwong D Cancers (Basel). 2024; 16(5).
PMID: 38473281 PMC: 10931083. DOI: 10.3390/cancers16050919.
Zhou X, Matskova L, Zheng S, Wang X, Wang Y, Xiao X Front Cell Dev Biol. 2022; 10:861916.
PMID: 35938161 PMC: 9353648. DOI: 10.3389/fcell.2022.861916.
Liang Y, Zhang Y, Tan X, Qiao H, Liu S, Tang L Nat Commun. 2022; 13(1):2996.
PMID: 35637194 PMC: 9151760. DOI: 10.1038/s41467-022-30709-6.
Li X, Guo D, Chu L, Huang Y, Zhang F, Li W Cancer Manag Res. 2020; 11:9631-9640.
PMID: 32009818 PMC: 6861168. DOI: 10.2147/CMAR.S222756.
Guo D, Li X, Xie A, Cao Q, Zhang J, Zhang F J Clin Lab Anal. 2019; 34(4):e23132.
PMID: 31755593 PMC: 7171299. DOI: 10.1002/jcla.23132.